Advertisement

Related Videos

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Opportunities to Optimize Cancer Policies Panel Discussion

Amit Sanyal, MD: A Clinician’s Perspective

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Apr
04
Today In Oncology
Study Finds GLP-1RAs Were Associated With a Reduced Risk of Developing Colorectal Cancer vs Aspirin
FDA Grants Traditional Approval to Brexucabtagene Autoleucel for Relapsed or Refractory MCL
AI Shows Dermatologist-Level Accuracy in Melanoma Diagnosis but Needs Validation
Prompting Strategies Improve Symptom Monitoring in Childhood Cancer Survivors
Patients With Lung Cancer May Safely Receive Adequate SBRT Dosage in One Treatment
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo